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PARTICIPANTS WHO WOULD BENEFIT: All re-
searchers who conduct outcomes and/or pharmacoeco-
nomic evaluations of medical technology; pharmaceutical
and device industry managers responsible for design and
implementation of clinical trials and naturalistic studies.
Women’s health research has historically focused on dis-
eases affecting fertility and reproduction. Women were
often excluded from clinical trials on other diseases (e.g.,
heart disease) due to concerns about exposure to drugs
during reproductive years, concerns about hormonal ef-
fects complicating results, and an assumption that results
for men are applicable to women. Several organizations
have begun to address these issues, including the NIH
Office of Research on Women’s Health, the Society for
the Advancement of Women’s Health Research, and the
pharmaceutical industry. This workshop will provide a
brief history of the development of the field of women’s
health research, an overview of the political and scientific
forces that have shaped the field, and a review of current
foci for women’s health researchers. Guidelines from rep-
resentative organizations regarding a woman’s health re-
search agenda will be reviewed. Specific methodological
issues that arise from exploration of gender differences
will be identified and a rationale for examining gender ef-
fects will be presented. Discussion will focus on ways in
which outcomes research, especially clinical trials and ef-
fectiveness studies, can be designed to address gender ef-
fects and gaps in knowledge about women’s health.
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Ministry of Health, Jerusalem, Israel
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to identify the economic data needed for the
decision-maker in order to make his decision. The rea-
sons for which economic evaluation has a relatively low
impact on healthcare decision-making and interventions
that could change this situation, will be discussed.
PARTICIPANTS WHO WOULD BENEFIT: Govern-
ment and healthcare industry decision-makers and other
professionals involved in submitting economic evalua-
tions to decision-makers.
Israel’s Health Insurance Law states that health services
included in the List of Health Services will be of reason-
able quality within the framework of the funding sources
available. The inherent scarcity of resources for health
services in Israel, like in other western countries, together
with the rapid development of new and expensive health
technologies makes updating the list of health services a
complicated task. The Pharmaceutical Administration set
up a mechanism for updating the National List of Reim-
bursed Pharmaceuticals (NLRD) which is a part of the
obligatory List of Health Services each citizen is entitled
to get. The Pharmaceutical Administration took a sys-
tematic approach of health technology assessment: Ad-
hoc teams were established for evaluating clinical safety,
efficacy and effectiveness, conducting needs assessment
and economic analysis. An initial filtering process was
taken in order to screen only beneficial and affordable
technologies. This procedure leads to a list of new phar-
maceuticals suggested for inclusion in the NLRD. In this
workshop, we will present the current policy concerning
economic evaluation in Israel and the planned policy,
covering issues such as submission of a dossier which in-
cludes important parameters like drug prices and their
justification, affordability of the new drug and a specified
economic analysis.
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EXPERIENCE WITH RESEARCH DATA
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Blue Cross and Blue Shield of Massachusetts, Boston, MA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to review the results of a major Blue Cross and
Blue Shield plan sharing its data with health researchers
since 1995. Participants will learn about the kinds of or-
ganizations using the data, the disease areas studied, the
operational requirements of creating usable research data
bases from health claims and the administrative issues of
data provision including confidentiality.
PARTICIPANTS WHO WOULD BENEFIT: Users and
potential users of administrative data seeking an under-
standing of the actual uses of claims data.
Since 1995, Blue Cross and Blue Shield of Massachusetts
has supplied quality data specifically created for third-party
research from its archives representing 1.8 million covered
lives. During the last 4 years, some clear patterns have de-
veloped in the kinds of organizations using the data—these
trends will be discussed. Certain therapeutic areas stand
out as having been of most interest to the research commu-
nity—a breakdown of these will be presented. BCBSMA
data cover the full spectrum of healthcare utilization: inpa-
tient, outpatient, professional provider, prescription drugs
(mail and pharmacy channels), plus enrollment. Historical
data are available for up to 5 years. Maintaining a reliable
and high-quality data resource requires organizational
commitment and efficient operation ensuring long-term
survival. At BCBSMA, research data are supplied through a
dedicated function using existing archival resources and
tailoring the data for external health research. Sharing
members’ data is a very sensitive matter in a business that
depends upon excellent member relationships. The decision
to make data available is only workable in the context of
careful partner selection, member identity encryption, and
organizational confidentiality. While far from perfect,
claims have the advantage of representing actual practice
and costs in naturalistic populations.
